CN101528212A - Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物 - Google Patents

Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物 Download PDF

Info

Publication number
CN101528212A
CN101528212A CNA2007800361811A CN200780036181A CN101528212A CN 101528212 A CN101528212 A CN 101528212A CN A2007800361811 A CNA2007800361811 A CN A2007800361811A CN 200780036181 A CN200780036181 A CN 200780036181A CN 101528212 A CN101528212 A CN 101528212A
Authority
CN
China
Prior art keywords
saha
hdac inhibitor
pharmaceutical composition
cancer
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800361811A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·麦克奥恩
T·A·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101528212A publication Critical patent/CN101528212A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800361811A 2006-09-28 2007-09-24 Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物 Pending CN101528212A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84830006P 2006-09-28 2006-09-28
US60/848,300 2006-09-28

Publications (1)

Publication Number Publication Date
CN101528212A true CN101528212A (zh) 2009-09-09

Family

ID=39230785

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800361811A Pending CN101528212A (zh) 2006-09-28 2007-09-24 Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物

Country Status (14)

Country Link
US (2) US20090239946A1 (ru)
EP (2) EP2436382A1 (ru)
JP (1) JP2010504968A (ru)
KR (1) KR20090064400A (ru)
CN (1) CN101528212A (ru)
AU (1) AU2007300532A1 (ru)
BR (1) BRPI0717554A2 (ru)
CA (1) CA2663569A1 (ru)
CO (1) CO6190508A2 (ru)
IL (1) IL197718A0 (ru)
MX (1) MX2009003405A (ru)
NO (1) NO20091664L (ru)
RU (1) RU2009115860A (ru)
WO (1) WO2008039421A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362148A (zh) * 2017-07-27 2017-11-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678165C (en) * 2003-11-17 2013-11-05 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
CN101389617A (zh) * 2005-10-31 2009-03-18 詹森药业有限公司 制备哌嗪基和二氮杂环庚烷基苯甲酰胺衍生物的新方法
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
EP2349985A2 (en) 2008-10-15 2011-08-03 Generics [UK] Limited Process for the preparation of vorinostat
WO2010062333A1 (en) * 2008-10-27 2010-06-03 Plus Chemicals Sa Polymorphs of vorinostat and vorinostat potassium salt and process for preparation thereof
WO2010061219A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Polymorphs
US8343970B2 (en) 2010-03-12 2013-01-01 Omeros Corporation PDE10 inhibitors and related compositions and methods
SG10201506865WA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN104955452B (zh) * 2013-09-05 2017-06-09 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
RU2017134509A (ru) 2015-04-24 2019-04-04 Омерос Корпорейшн Ингибиторы pde10 и соответствующие композиции и способы
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN114829375A (zh) * 2019-10-07 2022-07-29 维拉克塔附属公司 具有降低的副作用的hdac治疗的剂量
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574822A (en) * 1976-03-23 1980-09-10 Lafon Labor Acetohydroxamic acid derivatives and pharmaceutical compositions thereof
US4315942A (en) * 1979-05-21 1982-02-16 New England Medical Center, Inc. Intravenously administrable iron supplement
US4335116A (en) * 1980-10-07 1982-06-15 University Patents, Inc. Mineral-containing therapeutic compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4613616A (en) * 1984-07-20 1986-09-23 Research Corporation Polymeric iron chelators
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
JPH11514857A (ja) 1995-09-20 1999-12-21 メルク エンド カンパニー インコーポレーテッド 抗原虫剤の標的としてのヒストンデアセチラーゼ
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
EP1212357B1 (en) * 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
CN1378450A (zh) 1999-09-08 2002-11-06 斯隆-凯特林癌症研究院 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040018968A1 (en) * 2002-04-15 2004-01-29 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
WO2006026260A1 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Histone deacetylase inhibitors
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) * 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362148A (zh) * 2017-07-27 2017-11-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用

Also Published As

Publication number Publication date
NO20091664L (no) 2009-04-27
US20120142770A1 (en) 2012-06-07
WO2008039421A3 (en) 2008-07-24
EP2436382A1 (en) 2012-04-04
CO6190508A2 (es) 2010-08-19
US20090239946A1 (en) 2009-09-24
EP2079462A4 (en) 2009-12-02
RU2009115860A (ru) 2010-11-20
IL197718A0 (en) 2009-12-24
CA2663569A1 (en) 2008-04-03
BRPI0717554A2 (pt) 2013-10-29
KR20090064400A (ko) 2009-06-18
WO2008039421A2 (en) 2008-04-03
AU2007300532A1 (en) 2008-04-03
JP2010504968A (ja) 2010-02-18
EP2079462A2 (en) 2009-07-22
MX2009003405A (es) 2009-04-09

Similar Documents

Publication Publication Date Title
CN101528212A (zh) Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物
CN1964714B (zh) 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
EP2082737B1 (en) Methods of inducing terminal differentiation
EP1663194B1 (en) Use of SAHA for treating mesothelioma
US7148257B2 (en) Methods of treating mesothelioma with suberoylanilide hydroxamic acid
CN101300015A (zh) 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
CN101528037A (zh) 使用saha和硼替佐米治疗多发性骨髓瘤的方法
WO2007056243A2 (en) Methods of treating cancers with saha and fluorouracil and other combination therapies
CN101516191A (zh) Saha的胺碱盐和其多晶型物
CN1870985B (zh) 用hdac抑制剂治疗癌症的方法
Richon et al. Methods of treating Hodgkin's and non-Hodgkin's lymphoma
KR20050020760A (ko) 말단 분화의 유도 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090909